Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Drugs for Alzheimer's
Gonzalo Emiliano Aranda-Abreu1*, María Elena Hernández-Aguilar1, Marisol Herrera-Rivero2 and Luis Isauro García-Hernández11Centro de Investigaciones Cerebrales/Universidad Veracruzana, Cuerpo Académico de Neuroquímica, Xalapa,Veracruz, México
2Doctorado en Ciencias Biomédicas/Universidad Veracruzana, Centro de Investigaciones Biomédicas, Xalapa, Veracruz, México
- *Corresponding Author:
- Gonzalo Emiliano Aranda-Abreu
Centro de Investigaciones Cerebrales/Universidad Veracruzana
Cuerpo Académico de Neuroquímica
Av. Luis Castelazo Ayala
Km 3.5 Carretera Xalapa-Veracruz 91190; México
Tel: 52 228 8418900 Ext. 13616
Fax: 52 228 8418920
E-mail: garanda@uv.mx
Received November 14, 2011; Accepted January 09, 2012; Published January 08, 2012
Citation: Aranda-Abreu GE, Hernández-Aguilar ME, Herrera-Rivero M, García-Hernández LI (2012) Drugs for Alzheimer’s. J Addict Res Ther S5:003. doi:10.4172/2155-6105.S5-003
Copyright: © 2012 Aranda-Abreu GE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Five drugs are currently approved for the treatment of Alzheimer’s disease; nevertheless, we have faced the challenge to respond to family members of these patients the reason why they observe a limited improvement from these treatments. Although both acetylcholinesterase inhibitors and memantine are correctly designed and they show an adequate performance, we believe the neuronal conditions resulting from the pathophysiology of the disease difficult their proper working in brains affected with Alzheimer’s. Patients should therefore undergo a neuronal rehabilitating therapy that enables these drugs for a more effective performance.
